GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
P

Pfizer PFE · USD

Health Care · Pharmaceuticals · US listing · 🇺🇸 United States

S&P 500

Compare

29.23

-0.54%

Close of 9 Nov 2026, in USD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in USD, from our data supplier.

FY2025

Revenue

$62.58bn

FY2016FY2025

Net income

$7.77bn

FY2016FY2025

Free cash flow

$9.08bn

FY2016FY2025

Shareholders' equity

$86.48bn

FY2016FY2025

Income statement

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue$62.58bn$63.63bn$59.55bn$100.33bn$81.29bn$41.65bn$41.17bn$53.65bn$52.55bn$52.82bn
Research and development$11.98bn$10.74bn$10.58bn$11.43bn$13.83bn$9.39bn$8.36bn$7.97bn$7.64bn$7.84bn
Operating income$10.19bn$10.57bn$5.29bn$37.55bn$22.05bn$9.09bn$7.51bn$15.29bn$14.39bn$9.54bn
Net income$7.77bn$8.02bn$2.13bn$31.36bn$22.15bn$9.16bn$16.27bn$11.15bn$21.30bn$7.21bn
Diluted earnings per share1.371.410.385.463.841.622.891.933.511.17

Balance sheet

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Total assets$208.16bn$213.40bn$226.50bn$197.21bn$181.48bn$154.23bn$167.49bn$159.42bn$171.80bn$171.62bn
Cash and short-term investments$13.60bn$20.48bn$12.69bn$22.73bn$31.07bn$12.22bn$9.83bn$18.83bn$19.99bn$17.85bn
Total liabilities$121.39bn$124.90bn$137.21bn$101.29bn$104.01bn$90.76bn$104.04bn$95.66bn$100.14bn$111.78bn
Debt$65.13bn$64.35bn$71.89bn$35.83bn$38.44bn$39.84bn$52.15bn$41.74bn$43.49bn$42.09bn
Shareholders' equity$86.48bn$88.20bn$89.29bn$95.92bn$77.46bn$63.47bn$63.45bn$63.76bn$71.66bn$59.84bn
Shares outstanding5,686m5,703m5,647m5,743m5,768m5,662m5,631m5,788m6,064m6,144m

Cash flow

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash from operations$11.71bn$12.74bn$8.70bn$29.27bn$32.58bn$14.40bn$12.59bn$15.83bn$16.47bn$15.90bn
Capital spending−$2.63bn−$2.91bn−$3.91bn−$3.24bn−$2.71bn−$2.79bn−$2.59bn−$2.20bn−$2.22bn−$2.00bn
Free cash flow$9.08bn$9.84bn$4.79bn$26.03bn$29.87bn$11.61bn$9.99bn$13.63bn$14.25bn$13.90bn
Dividends paid−$9.77bn−$9.51bn−$9.25bn−$8.98bn−$8.73bn−$8.44bn−$8.04bn−$7.98bn−$7.66bn−$7.32bn

Latest quarters

By quarter end

Jun 2026Mar 2026Dec 2025Sept 2025Jun 2025Mar 2025Dec 2024Sept 2024
Revenue$15.03bn$14.45bn$17.56bn$16.65bn$14.65bn$13.71bn$17.76bn$17.70bn
Operating income$4.71bn$4.03bn$3.69bn$6.07bn$4.32bn$4.97bn$5.72bn$5.99bn
Net income−$246.0m$2.69bn−$1.65bn$3.54bn$2.91bn$2.97bn$403.0m$4.46bn
Diluted earnings per share-0.040.47-0.290.620.510.520.070.78
Cash from operations$835.0m$2.62bn$5.35bn$4.60bn−$582.0m$2.33bn$6.72bn$6.71bn
Capital spending−$533.0m−$436.0m−$845.0m−$602.0m−$618.0m−$564.0m−$917.0m−$651.0m
Free cash flow$302.0m$2.18bn$4.50bn$4.00bn−$1.20bn$1.77bn$5.80bn$6.06bn
Total assets$201.13bn$207.62bn$208.16bn$208.73bn$206.09bn$208.03bn$213.40bn$219.48bn
Cash and short-term investments$11.70bn$13.07bn$13.60bn$14.98bn$13.25bn$17.32bn$20.48bn$9.95bn
Debt$63.19bn$63.73bn$65.13bn$61.71bn$61.80bn$62.11bn$64.35bn$67.70bn
Shareholders' equity$85.19bn$90.10bn$86.48bn$92.80bn$88.69bn$90.34bn$88.20bn$92.29bn

Financial ratios

Data as of 6 Sept 2026

FY2025FY2024FY2023FY2022FY2021FY2020
Operating margin16.3%16.6%8.9%37.4%27.1%21.8%
Net margin12.4%12.6%3.6%31.3%27.2%22.0%
Return on equity9.0%9.1%2.4%32.7%28.6%14.4%
Return on assets3.7%3.8%0.9%15.9%12.2%5.9%
Free cash flow yield8.9%9.6%7.8%19.9%21.5%10.7%
Revenue growth-1.6%6.8%-40.6%23.4%95.2%1.2%
Earnings growth-3.1%276.0%-93.2%41.6%141.8%-43.7%
Current ratio1.16x1.17x0.91x1.22x1.40x1.35x
Debt to equity0.74x0.73x0.80x0.37x0.50x0.63x
Equity ratio41.5%41.3%39.4%48.6%42.7%41.2%
Interest coverage3.82x3.42x2.40x30.33x17.08x6.27x
R&D as a share of sales19.1%16.9%17.8%11.4%17.0%22.6%
Buybacks as a share of market value0.3%-1.0%1.7%0.4%-1.9%-0.6%

Growth per year

Compound annual rate

3 years5 years10 years
Revenue-14.6%8.5%2.5%
Operating income-35.3%2.3%-2.6%
Net income-37.2%-3.2%1.1%

Average margins

Over each period

1 year3 years5 years10 years
Operating margin16.4%22.2%23.2%23.5%
Net margin12.5%17.2%19.7%21.8%

Valuation history

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Price to earnings18.218.976.29.415.422.813.622.610.327.7
Price to sales2.32.42.72.94.25.05.44.74.23.8

Market value over time

31 Oct 2016 to 4 Sept 2026, in USD

$184.38bn$162.14bn

Share price return

Finished calendar years

2025202420232022202120202019201820172016
Return-3%-8%-45%-16%63%-5%-6%15%11%3%

Dividends and splits

Per share, in the currency the company pays

Paid for 36 years. Last went ex-dividend on 24 Jul 2026.

FY2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019
Paid in the year0.861.721.692.061.611.571.531.46
  • 1-to-1 reverse split · 24 Jun 2013
  • 3-for-1 split · 1 Jul 1999
  • 2-for-1 split · 1 Jul 1997
  • 2-for-1 split · 3 Jul 1995
  • 2-for-1 split · 1 Apr 1991

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.